Utility of a dedicated pediatric cardiac anticoagulation program: the Boston Children's Hospital experience
- PMID: 25573076
- DOI: 10.1007/s00246-014-1089-x
Utility of a dedicated pediatric cardiac anticoagulation program: the Boston Children's Hospital experience
Abstract
Congenital heart disease is the leading cause of stroke in children. Warfarin therapy can be difficult to manage safely in this population because of its narrow therapeutic index, multiple drug and dietary interactions, small patient size, high-risk cardiac indications, and lack of data to support anticoagulation recommendations. We sought to describe our institution's effort to develop a dedicated cardiac anticoagulation service to address the special needs of this population and to review the literature. In 2009, in response to Joint Commission National Patient Safety Goals for Anticoagulation, Boston Children's Hospital created a dedicated pediatric Cardiac Anticoagulation Monitoring Program (CAMP). The primary purpose was to provide centralized management of outpatient anticoagulation to cardiac patients, to serve as a disease-specific resource to families and providers, and to devise strategies to evolve clinical care with rapidly emerging trends in anticoagulation care. Over 5 years the CAMP Service, staffed by a primary pediatric cardiology attending, a full-time nurse practitioner, and administrative assistant with dedicated support from pharmacy and nutrition, has enrolled over 240 patients ranging in age from 5 months to 55 years. The most common indications include a prosthetic valve (34 %), Fontan prophylaxis (20 %), atrial arrhythmias (11 %), cardiomyopathy (10 %), Kawasaki disease (7 %), and a ventricular assist device (2 %). A patient-centered multi-disciplinary cardiac anticoagulation clinic was created in 2012. Overall program international normalized ratio (INR) time in therapeutic range (TTR) is favorable at 67 % (81 % with a 0.2 margin) and has improved steadily over 5 years. Pediatric-specific guidelines for VKOR1 and CYP2C9 pharmacogenomics testing, procedural bridging with enoxaparin, novel anticoagulant use, and quality metrics have been developed. Program satisfaction is rated highly among families and providers. A dedicated pediatric cardiac anticoagulation program offers a safe and effective strategy to standardize anticoagulation care for pediatric cardiology patients, is associated with high patient and provider satisfaction, and is capable of evolving care strategies with emerging trends in anticoagulation.
Similar articles
-
Safety and Efficacy Outcomes of Home and Hospital Warfarin Management Within a Pediatric Anticoagulation Clinic.J Pediatr Hematol Oncol. 2016 Apr;38(3):216-20. doi: 10.1097/MPH.0000000000000502. J Pediatr Hematol Oncol. 2016. PMID: 26808370
-
Safety and efficacy of warfarin in paediatric patients with prosthetic cardiac valves: a retrospective audit.Thromb Res. 2011 Oct;128(4):331-4. doi: 10.1016/j.thromres.2011.04.020. Epub 2011 May 26. Thromb Res. 2011. PMID: 21620442
-
Does telehealth improve anticoagulation management in patient service centers (PSC)? A pilot project.J Thromb Thrombolysis. 2020 Feb;49(2):316-320. doi: 10.1007/s11239-019-02031-4. J Thromb Thrombolysis. 2020. PMID: 31898275
-
Self-management of anticoagulation.Expert Rev Cardiovasc Ther. 2008 Aug;6(7):979-85. doi: 10.1586/14779072.6.7.979. Expert Rev Cardiovasc Ther. 2008. PMID: 18666848 Review.
-
Prevention of stroke in patients with atrial fibrillation.Semin Vasc Med. 2005 Aug;5(3):285-92. doi: 10.1055/s-2005-916168. Semin Vasc Med. 2005. PMID: 16123916 Review.
Cited by
-
Improving Anticoagulation Care for Pediatric Oncology Patients: A Quality Improvement Initiative.Pediatr Qual Saf. 2024 Feb 9;9(1):e720. doi: 10.1097/pq9.0000000000000720. eCollection 2024 Jan-Feb. Pediatr Qual Saf. 2024. PMID: 38344690 Free PMC article.
-
An evidence-based standardized protocol for anticoagulation following congenital heart surgery.Transl Pediatr. 2018 Oct;7(4):369-371. doi: 10.21037/tp.2018.07.04. Transl Pediatr. 2018. PMID: 30460190 Free PMC article. No abstract available.
-
The Evolution of a Pediatric Ventricular Assist Device Program: The Boston Children's Hospital Experience.Pediatr Cardiol. 2017 Jun;38(5):1032-1041. doi: 10.1007/s00246-017-1615-8. Epub 2017 Apr 29. Pediatr Cardiol. 2017. PMID: 28456829
-
Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease.J Thromb Haemost. 2023 Jun;21(6):1601-1609. doi: 10.1016/j.jtha.2023.03.005. Epub 2023 Mar 14. J Thromb Haemost. 2023. PMID: 36921920 Free PMC article.
-
Guiding warfarin self-management in children: development of a warfarin nomogram.Res Pract Thromb Haemost. 2023 Nov 10;7(8):102255. doi: 10.1016/j.rpth.2023.102255. eCollection 2023 Nov. Res Pract Thromb Haemost. 2023. PMID: 38193059 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous